Introduction
============

A large body of evidence from various disciplines indicates that common nonsteroidal anti-inflammatory drugs (NSAIDs) have an impressive potency in the prevention of colorectal cancer (reviewed in [@b3-btt-2-329]). The antineoplastic activity of NSAIDs has been attributed to their ability to inhibit the prostaglandin synthases, particularly cyclooxygenase-2 (COX-2), which is overexpressed in and responsible for the high levels of prostaglandins (PGs) such as PGE~2~ in colorectal cancer (CRC). PGs bind to specific receptors, thereby inducing pleiotropic effects on processes such as proliferation, apoptosis, differentiation, migration, angiogenesis, and immunosuppression ([@b3-btt-2-329]). Despite numerous studies, however, no pathway downstream of the PG receptors has been described to date that is consistently affected by NSAIDs. Possible explanations for this apparent mechanistic heterogeneity include cell line-, organism-, and drug-specific effects.

In this study, we aimed to estimate the level of heterogeneity with which different CRC cell lines react to inhibition of COX-2. We analyzed by microarray the expression response of CRC cells following treatment with an irreversible COX-2 inhibitor (CIB) at a dose which specifically reduced colony formation of COX-2 expressing CRC cells. Based on confirmation by quantitative polymerase chain reaction (QPCR), our results indicate that each cell line responds individually to COX-2 inhibition. However, the observation that components of the WNT pathway were similarly affected in COX-2 expressing cells suggests potential common mechanisms underlying CIB action may exist.

Materials and methods
=====================

Cell lines and drug treatment
-----------------------------

APHS (o-(acetoxyphenyl)hept-2-ynyl sulfide; Cayman Chemical, Ann Arbor, MI, USA) was dissolved in dimethyl sulfoxide (DMSO) under N~2~ at 100 mM and stored at −20 °C. SW480, SW620, CaCo-2, and HT-29 cells were from the American Type Culture Collection. HCA-7 was a kind gift from S.C. Kirkland ([@b13-btt-2-329]). Cells were grown in DMEM with 5% fetal bovine serum (FBS) at 5% CO~2~ with the addition of 0.01 mg/ml transferrin for CaCo-2 cells. Single cell suspensions were prepared by passage through a 0.4 mm needle. Cells were seeded at 200--400 cells/cm^2^, treated with APHS or vehicle 24 h later and left to form colonies for 7--10 days. DMSO (vehicle) concentration was kept below 1% in all experiments. Colonies were stained with 1% Crystal Violet, photographed and total cellular area was measured using National Institutes of Health (NIH) Image software (<http://rsb.info.nih.gov/nih-image/>).

Microarray analysis
-------------------

For microarray analysis, cells were seeded at 5800 cells/cm^2^ and treated with 40 μM APHS or 0.4% DMSO 24 h later (before colony growth onset). Total RNA was isolated 48 h following treatment. Initial pilot experiments suggested that at this time point, first significant expression changes induced by APHS were detectable. Sample and reference cDNAs (pooled samples of cells at 0 and 48 h after treatment with vehicle) were Cy3/Cy5-labeled and hybridized (40 μg) as duplicates to arrays duplicate-printed with the '6017 human cDNA clone set' (Research Genetics). The procedure followed the protocols developed by Dr. J. DeRisi, University of California, San Francisco (see <http://www.microarrays.org>). Feature selection was performed using GenePix 4.0 software (Axon Instruments, Inc, Foster City, CA, USA). Expression data were normalized using SNOMAD (Standardization and Normalization of MicroArray Data), which first performs background subtraction to include only spots with intensities over background, then performs global mean normalization and local mean normalization across the array surface (Loess), followed by local mean normalization and local variance correction across the spot signal intensity (for details see <http://pevsnerlab.kennedykrieger.org/snomadinput.html>). Manual filtering was performed visually by flagging out any irregular or faint spots and yielded 5429 quantifiable gene spots. For each gene, the APHS-induced expression change relative to DMSO treatment was calculated (ΔZ = Z~APHS~−Z~DMSO~, where Z equals the normalized logarithmic standard deviation from the mean). ΔZ-gene lists were then searched for genes that were differentially expressed in coxP cell lines relative to the coxN cell lines to obtain genes specifically altered in cells responding to APHS with growth inhibition. The geometric ΔZ mean value of a gene from all coxP cells was compared to that of all coxN cells (BRB-ArrrayTool version 3.3; developed by Dr. Richard Simon and Amy Peng Lam, <http://linus.nci.nih.gov/~brb/>, 'class comparison' using an unpaired t-test assuming unequal variance with p = 0.005, 2000 permutations and Bonferroni-corrected for multiple testing). Similarly, ΔZ values from each individual coxP cell line were compared with the ΔZ mean of coxN cells to obtain cell-line specific gene expression changes.

To detect multiple gene expression changes that are part of a pathway (sets of interacting genes as defined by the Kegg and Biocarta pathway data bases), BRB-ArrayTools' 'pathway comparison' was used. In this test, a p-value based on a t-test is assigned to the ΔZ value of each gene of a given pathway. The set of p-values is summarized by the non-parametric LS and KS summary statistics to test whether the p-values have a uniform distribution. By computing the empirical distributions of the summary statistics in random gene set samples derived from the total gene set, the hypothesis is tested whether the pathway gene set contains more genes differentially expressed between the classes compared than would be expected by chance (at a significance level \<0.005 and 10^5^ permutations). Thus, a differentially expressed pathway can consist of genes that are not significantly altered at the single gene level (t-test p \> 0.005), however, the distribution of their alterations is non-random. Using this test, we compared ΔZ values of each individual coxP cell line with the ΔZ mean of the coxN cells to detect cell line-specific, differentially expressed pathways. To detect very small changes in pathway gene sets, we combined the coxP cells and compared their mean ΔZ values with that of the coxN cells. The RARA pathway was detected using PathwayAssist (Iobion) which searches interactions reported in the literature rather than screening public data bases. The colonic differentiation cluster was created by selecting genes linked to the term 'colon epithelium differentiation' using PubMatrix (see <http://pubmatrix.grc.nia.nih.gov/secure-bin/index.pl>) from a list of genes that were contained in the 6K cDNA set and assigned the ontology term 'differentiation'.

Quantitative real-time PCR
==========================

Based on the microarray pathway analysis, genes that represented a given pathway (upstream, central, and downstream relative to a pathway) were selected for confirmation by QPCR performed on the cDNA samples as used for microarray. Primers and probes for all genes were purchased as Assay-OnDemand (AppliedBiosystems, Victoria, Australia), with the exception of the primers/probes for *COX2* and the control *ACTB (β-actin),* which are described by [@b10-btt-2-329]. The cycle numbers (Ct) of analyzed genes were below 36. Relative expression was expressed as 2^−ΔCt^, with ΔCt = Ct~gene~--Ct~actin~. SD was determined from triplicate measurements of ΔCt values. SD of relative expression was estimated as SD~rel~ =(2^−(ΔCt−SD)^ -- 2^−(ΔCt\ +SD)^)/2 ([@b10-btt-2-329]).

Results
=======

In order to investigate whether different CRC cell lines display a heterogeneous response towards inhibition of COX-2 or whether their response includes common components, we used microarrays to obtain global expression profiles following growth inhibition of CRC cells by the irreversible CIB APHS ([@b11-btt-2-329]).

The effects of APHS were assessed using colony formation assays on the following five cell lines: HCA-7, CaCo-2, HT-29 (coxP: positive for *COX2* expression as assessed by QPCR; not shown), SW480 and its metastatic derivative SW620 (coxN: negative for *COX2* expression). The APHS concentration required to inhibit colony formation by 50% (IC~50~) compared to vehicle-treated controls was 14 μM for HT-29, 37 μM for CaCo-2, 48 μM for HCA-7, 67 μM for SW620, and 78 μM for SW480 cells ([Figure 1A](#f1-btt-2-329){ref-type="fig"}). The lower IC~50~ of APHS for coxP cells is likely due to COX-2 inhibition, as (i) APHS blocks COX-2 \>15x stronger than COX-1, and (ii) COX-1 expression in the cell lines measured by QPCR did not correlate with the APHS effects (not shown).

Based on the dose-response experiments, 40 μM APHS was chosen and inhibited the growth of coxP cell lines at least 50% whilst having little effect on coxN CRC cells. This APHS dose induced a similar response in colony formation assays where cells were seeded at a density sufficiently high to extract RNA for array hybridization ([Figure 1B](#f1-btt-2-329){ref-type="fig"}).

Forty-eight hours after treatment with APHS or vehicle, RNA was isolated to generate expression profiles using cDNA arrays. Unsupervised hierarchical clustering of the profiles revealed co-clustering of sample duplicates. Further, APHS-and vehicle-treated samples of coxN cells clustered together. In contrast, APHS-treated samples of coxP cells clustered away from vehicle-treated samples, indicating that 40 μM APHS induced an expression response in coxP but not coxN cell lines (not shown).

Genes differentially expressed between the coxP and the coxN cell lines (BRB-ArrayTool, t-test, p ≤ 0.005) following APHS treatment were computed to enrich for genes related to the growth inhibitory effects of APHS. Overall, 49/5429 genes were deregulated in coxP cells relative to coxN cells ([Table 1](#t1-btt-2-329){ref-type="table"}).

Comparison of individual coxP cell lines with coxN cells revealed a heterogeneous response: 81%, 79%, and 86% of the differentially expressed genes were specific to HT-29, CaCo-2, and HCA-7 cells, respectively. None of these genes was altered in all three cell lines simultaneously ([Figure 1C](#f1-btt-2-329){ref-type="fig"}, [Table 2](#t2-btt-2-329){ref-type="table"}). These data suggest that the expression response of CRC cells towards COX-2 inhibition by APHS is cell line-dependent to a large extent.

To search for biological themes in the response to COX-2 inhibition, expression profiles were analyzed for APHS-affected pathways using BRB-ArrayTools' pathway comparison. When individual coxP cell lines were compared to coxN cells, seven pathways appeared altered in HT-29 cells, eight in CaCo-2 cells and five in HCA-7 cells ([Table 3](#t3-btt-2-329){ref-type="table"}).

Each pair of coxP cell lines shared only one pathway ([Figure 1C](#f1-btt-2-329){ref-type="fig"}, [Table 2](#t2-btt-2-329){ref-type="table"}). Together, 15 of the 18 detected unique pathways were specific to a given cell line, consistent with a heterogeneous, cell line-dependent expression response of CRC cells towards APHS. An alternative pathway search was performed using PathwayAssist software, retrieving only one additional pathway (the retinoic acid receptor-α pathway) altered specifically in CaCo-2 cells.

QPCR was performed on selected genes to confirm cell line-specific alterations in cancer-related pathways. Following treatment with APHS, HT-29 cells but not other cell lines displayed downregulation of prion pathway components ([Figure 2A](#f2-btt-2-329){ref-type="fig"}). Likewise, CaCo-2 cells reacted with upregulation of the retinoic acid receptor-α gene and several of its downstream targets, while HCA-7 cells showed decreased expression of genes related to a hypoxia/stress-induced pathway ([Figure 2B/C](#f2-btt-2-329){ref-type="fig"}). For the majority of genes assayed by QPCR, expression trends were similar between QPCR and microarray data ([Table 4](#t4-btt-2-329){ref-type="table"}).

To detect low significance changes that may be common to coxP cells, mean ΔZ-data from all coxP cell lines were combined and compared to mean ΔZ-data from coxN cells. Pathway analysis suggested five pathways commonly affected by APHS in the coxP cells ([Table 5](#t5-btt-2-329){ref-type="table"}).

Of those, the WNT pathway is thought to be the most relevant in CRC. QPCR demonstrated specific upregulation in coxP cells of *WIF1*, a physiological inhibitor of the pathway ([@b24-btt-2-329]), of *SMAD4*, which counteracts WNT signaling ([@b8-btt-2-329]), of *TLE1* (groucho), a repressor of β-catenin/Tcf-mediated transcription ([@b15-btt-2-329]), and no apparent change in *GSKβ3*, the kinase involved in β-catenin degradation ([@b8-btt-2-329]). The upregulation of WIF1, SMAD4 and TLE1 would be expected to counteract β-catenin-mediated transcription. *MYC*, a transcriptional β-catenin target and a growth mediator ([@b8-btt-2-329]), was unaltered in coxP cells, but was upregulated in coxN cell lines ([Figure 2D](#f2-btt-2-329){ref-type="fig"}). This is consistent with APHS-mediated inhibition of WNT pathway activation in coxP cells treated at the beginning of the growth phase (24 h after seeding).

Discussion
==========

This study was performed to assess whether the response of CRC cells towards the CIB APHS is cell line-specific or contains common elements that may relate to the anticancer effects of this drug.

We first established an APHS dose that significantly affected the growth of only CRC cells expressing COX-2 and then applied this dose to study the drug effects by a microarray approach. Cluster analysis of the expression responses confirmed that the effects of APHS were specific for the coxP cells. To further select for genes likely associated with APHS-induced growth inhibition, only genes differentially expressed in coxP relative to coxN cells were included into analysis. The comparison of differentially expressed genes from each coxP cell line revealed that no gene was commonly affected in all three cell lines, even at the rather relaxed significance level (p = 0.005) applied. We then performed a search for pathways altered by APHS treatment. Again, none of the altered pathways was affected in all three cell lines simultaneously. Together, the array analysis suggested that APHS induces a heterogeneous expression response that is dependent on the studied CRC cell line.

Since microarray analysis can produce false results and is of limited sensitivity at the single gene level, we used the array output as a basis from which to investigate the APHS-induced expression response of CRC cells by QPCR. Therefore, it is important to stress that the biological interpretation of our findings is based on our QPCR-derived data.

Our QPCR results confirmed that APHS can affect pathways in a cell-line specific manner. QPCR indicated cell line-specific deregulation of genes from selected cancer-related pathways in individual coxP cell lines. The corresponding putative, underlying pathways and their biological effects are depicted in [Figure 2](#f2-btt-2-329){ref-type="fig"}. The pathway-associated gene alterations might represent mechanisms that contribute to the anticancer activity of CIBs. In HCA-7 cells for example, the genes encoding the prion protein and its receptor were downregulated by APHS. Both *PRNP* and *LAMR1* are known to be overexpressed in gastrointestinal disease ([@b6-btt-2-329]; [@b16-btt-2-329]), consistent with a tumor-inhibiting APHS effect. Likewise, the specific upregulation of the retinoic acid (RA) receptor-α gene and several RA-inducible genes in CaCo-2 cells may be tumor-suppressive ([@b1-btt-2-329]) and is of potential interest, as it suggests COX-2 inhibition might sensitize a subset of CRCs to the antineoplastic effects of RA. A possible explanation for this cell-specificity may lie in the different differentiation level of investigated cell lines. Clustering of the expression profiles of vehicle-treated cells with a set of genes involved in colonic differentiation indicated HT-29 cells to be least and CaCo-2 cells to be most differentiated (not shown). In line with this, PRNP expression appears to correlate with poor differentiation in gastric cancer ([@b16-btt-2-329]), while RA-receptor-α is a known differentiation inducer ([@b20-btt-2-329]). Together, these data suggest that COX-2 inhibition induces a cell line-specific expression response that is dependent on factors such as the cellular differentiation level.

In an attempt to detect low-significance changes which might be part of a common expression response towards APHS, we compared combined array data from all coxP cell lines with data from the coxN cells. Of the identified pathways, only the WNT pathway is both an established cancer pathway and known to be of direct relevance for CRC ([@b8-btt-2-329]). Confirmation by QPCR indicated small expression alteration that were common to all coxP cells and consistent with a downregulation of WNT signaling. These transcriptional alterations may not be significant on a single gene-level, explaining why they were detected by the less sensitive array approach only when cell lines were combined. However, their biologically meaningful direction and their simultaneous presence in all coxP cells is biologically significant. The WNT pathway as a possible APHS-target is an interesting finding, as the majority of CRCs harbor bi-allelic mutations in the *APC* tumor suppressor, leading to activation of the WNT pathway via stabilization of β-catenin. Importantly, the cell lines we investigated all have an activated WNT pathway, either due to *APC* mutation (HT-29, SW480/620, CaCo-2) or manifested as elevated transcriptional β-catenin activity (HCA-7) ([@b18-btt-2-329]; [@b9-btt-2-329]). Constitutive β-catenin activation is thought to be the key event in colorectal carcinogenesis, because it induces transcription of genes involved in self-renewal and malignant transformation ([@b8-btt-2-329]). Of those, *MYC* appears to be the most crucial target, as its conditional deletion alone is sufficient to revert the WNT pathway induced phenotype in vivo ([@b19-btt-2-329]; [@b25-btt-2-329]). The inhibition of *MYC* upregulation in the coxP cells following treatment may thus be related to the observed APHS-mediated growth inhibition. Notably, PGE~2~has recently been shown to stimulate β-catenin-mediated transcription ([@b7-btt-2-329]; [@b5-btt-2-329]; [@b23-btt-2-329]). Blocked PGE~2~ production due to APHS treatment may therefore cause WNT signaling repression. Our results suggest this inhibition also occurs at the transcriptional level of WNT pathway related genes. Whether these effects are direct and common to all CIBs remains to be determined. Clearly, pathways other than WNT signaling may be part of a common response to COX-2 inhibition. Some of these pathways may be included in [Table 2](#t2-btt-2-329){ref-type="table"}, however, their direct role in CRC cells has not been demonstrated yet. Alternatively, genes affected by APHS could be involved in pathways not represented in the searched databases or not contained in the used arrays. Also, pathways that are regulated mainly on the post-transcriptional level would remain undetected by our approach. However, the observation of similar expression changes in three unrelated coxP CRC cell lines suggests the WNT pathway may be a universal target of COX-2 inhibition by APHS. In support of our results, increasing evidence indicates a negative effect of various NSAIDs on WNT signaling both in vitro and in vivo ([@b4-btt-2-329]; [@b14-btt-2-329]; [@b26-btt-2-329]; [@b2-btt-2-329]; [@b17-btt-2-329]; [@b22-btt-2-329]; [@b12-btt-2-329]; [@b21-btt-2-329]).

In summary, our results indicate the cell line-dependent nature of expression changes induced by COX-2 inhibition and provide one explanation for the divergent molecular CIB targets identified to date. Likely, drug-specific effects will add to the heterogeneity of CRC cell line responses towards NSAIDs. However, APHS-mediated gene expression changes related to the WNT pathway could be identified that were shared by all COX-2 positive cell lines. These findings, together with the other reports on PGE~2~ and the WNT pathway, suggest a possible common mechanism underlying the effects COX-2 inhibition has on CRC growth. Given that WNT pathway activation is a very early event and has pleiotropic effects in colonic carcinogenesis, CIB-induced suppression of WNT activity could not only explain the preventive properties of NSAIDs, but also the variety of processes affected by these inhibitors. Thus, the WNT pathway is a promising candidate to explain some of the basic anticancer properties of COX-2 inhibitors.
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![APHS effects on CRC cell growth and EPs. (**A**) Dose-response curves of CRC cells. Relative colony formation is the ratio of total cellular area between APHS- and DMSO-treated cells. The average (±SD) of three independent triplicate experiments is shown. (**B**) APHS-induced growth inhibition of colonies seeded at three different cell densities: L (240/cm^2^), M (1200/cm^2^), and H (5800/cm^2^). The average (±SD) of two independent experiments is shown. (**C**) APHS-induced expression response in coxP CRC cells. Differential expression in coxP relative to coxN cell lines is plotted in Venn diagrams.](btt-2-329f1){#f1-btt-2-329}

![Expression by QPCR of selected genes from differentially expressed pathways. The charts show fold induction (±SD from triplicates) by APHS relative to DMSO treatment. The diagrams propose pathways that may underlie the observed expression changes. (**A**) Chronic inflammation mediated via COX-2 is associated with increased levels of prion protein. COX-2 inhibition may thus be related to reduced *PRNP* expression following APHS treatment. Prion protein binds to the laminin receptor 1 and can directly interact with Nfe2l2 (Nrf2), which is involved in reciprocal *COX2* regulation. *PRNP* downregulation may sensitize cancer cells to apoptotic stimuli, while *LAMR1* expression correlates with tumor progression. (**B**) Retinoic acid (RA) is well known for its anticancer effects and is essential for proper colonic differentiation. Activation of the RA receptor-α is known to inhibit the growth of CRC cells *in vitro*. Many genes have been identified that can be induced by RA or its α-receptor and all are involved in antineoplastic processes. Integrinβ4, however, can also promote metastatic behavior. (**C**) The COX-2 product PGE~2~ has been shown to regulate Hif1a, Akt1, and Mapk8 (Sapk or Jnk1), which further can modulate Igfbp3 and Fhl2 levels via p53. The inhibition of these proteins by CIBs can lead to cancer cell apoptosis and growth reduction, however, some CIBs can also require activation of proteins such as Mapk8 for their anticancer action. In addition, complex and often reciprocal interactions exist between these proteins. The exact role of this pathway in CRC is thus difficult to assess. (**D**) The WNT pathway is initiated by signaling through Fzd receptors causing inhibition of the Apc-containing complex normally required for degradation of cytoplasmic β-catenin. β-catenin in turn can accumulate, translocate to the nucleus and induce transcription of *MYC*, the key mediator of colonic proliferation and self-renewal. The majority of CRCs harbor mutations that lead to β-catenin accumulation. See main text for further details.](btt-2-329f2){#f2-btt-2-329}

###### 

Genes differentially expressed in coxP cells relative to coxN cells

  Geom mean coxP   Geom mean coxN   Ratio P/N   Identifier   Gene symbol
  ---------------- ---------------- ----------- ------------ -------------
  0.920            1.627            0.565       AA464600     MYC
  1.628            0.872            1.867       H65328       RAB11B
  2.527            0.940            2.687       AA448866     DVL2
  0.908            1.622            0.560       T50788       UGT2B15
  0.984            0.389            2.526       AA406364     GNAI1
  1.017            1.953            0.521       AA705886     MXI1
  1.220            0.251            4.855       AA504832     SP110
  0.903            0.459            1.969       H74265       PTPRC
  1.765            0.841            2.098       AA504336     MED16
  1.145            0.624            1.835       AA074446     GCHFR
  1.465            0.891            1.645       W31391       TJP2
  2.597            0.822            3.158       AA446120     ADM
  2.019            1.016            1.988       AA857343     TAF15
  1.057            0.440            2.403       AA477283     KLK11
  1.549            0.712            2.176       H29475       PDK2
  1.614            0.873            1.849       AA464532     THBS1
  1.861            1.030            1.808       AA421701     LRRC41
  1.044            0.667            1.565       AA282134     QPCT
  0.748            0.307            2.433       AA455235     ALDH1A3
  1.773            0.598            2.966       N74131       TFF3
  0.773            1.437            0.538       R26082       ZNF354A
  1.135            0.804            1.411       N55461       EPB49
  0.970            1.450            0.669       AA629909     GARS
  0.884            1.472            0.601       R68106       FCGR2B
  0.883            1.197            0.737       AA411202     AHSA1
  1.403            0.744            1.885       N50834       MVD
  0.887            1.235            0.718       AA418032     ARIH1
  1.204            0.829            1.453       AI209184     HIST1H2AE
  1.570            1.001            1.569       N54821       IL2RG
  0.930            0.278            3.344       AA458507     CSF3R
  0.931            0.447            2.082       AA131693     PTHLH
  0.846            1.467            0.577       W46900       CXCL1
  0.837            0.319            2.629       AA291742     PML
  0.835            1.367            0.611       N64508       PODXL
  6.713            1.096            6.124       R72432       JAG2
  1.260            0.846            1.489       AA057204     IL2RB
  3.160            0.884            3.575       AA055491     TSPAN12
  1.382            0.789            1.753       AA007560     PILRA
  3.137            0.973            3.223       R50337       SLC19A1
  0.975            1.379            0.707       AA455300     CSDA
  0.964            1.299            0.742       N33236       MRPS30
  2.193            0.961            2.282       AI969985     NF1
  1.385            0.831            1.667       AA443090     IRF7
  1.396            0.920            1.517       T67524       ZNF-like
  1.149            0.592            1.941       AA418015     NEURL
  1.424            0.658            2.164       AA152099     FZD4
  1.129            0.494            2.287       AA670429     SGNE1
  1.577            0.936            1.685       AA425437     IGSF3
  0.933            1.273            0.733       AA410636     IARS

**Notes:** For all listed genes: permutation p \< 0.005.

###### 

APHS-affected genes and pathways shared between individual coxP cell lines

  Common genes       
  ------------------ --------------------------------------------------------------------
  **HT-29/HCA-7**    *KLK10, AHSA1*
  **HT-29/CaCo-2**   *QPCT, AKR1C2*
  **HCA-7/CaCo-2**   *RPS6KA4, GCH1, GNB1, CD180, DAPK3, KIFC1, SLC19A1, SHC1, UGT2B15*

  Common pathways    Pathway Id[a](#tfn2-btt-2-329){ref-type="table-fn"}   Description                                                LS permutation p-value   KS permutation p-value
  ------------------ ----------------------------------------------------- ---------------------------------------------------------- ------------------------ ------------------------
  **HT-29/HCA-7**    **Kegg:** hsa00970                                    Aminoacyl-tRNA biosynthesis                                \<0.00001                \<0.0004
  **HT-29/CaCo-2**   **BioCarta:** h_nkcellsPathway                        Ras-independent pathway in NK cell-mediated cytotoxicity   \<0.003                  \<0.13
  **HCA-7/CaCo-2**   **BioCarta:** h_setPathway                            Granzyme A mediated apoptosis pathway                      \<0.003                  \<0.1

**Notes:** **^a^**Pathway accession under: <http://www.genome.jp/kegg/pathway.html> and <http://www.biocarta.com/>. Please use Pathway Id to retrieve pathways and the associated genes.

###### 

Unique pathways altered by APHS in individual coxP cell lines

  Pathway Id[a](#tfn3-btt-2-329){ref-type="table-fn"}   Description                                            LS permutation p-value   KS permutation p-value
  ----------------------------------------------------- ------------------------------------------------------ ------------------------ ------------------------
  **HT-29**                                                                                                                             
  **Kegg:** hsa00190                                    Oxidative phosphorylation                              \<0.0002                 \<0.009
  **BioCarta:** h_prionPathway                          Prion pathway                                          \<0.0008                 \<0.009
  **BioCarta:** h_eifPathway                            Eukaryotic protein translation                         \<0.002                  \<0.0004
  **BioCarta:** h_hcmvPathway                           Cytomegalovirus and Map kinase pathways                \<0.004                  \<0.22
  **Kegg:** hsa00100                                    Sterol biosynthesis                                    \<0.02                   \<0.004
  **HCA-7**                                                                                                                             
  **Kegg:** hsa00010                                    Glycolysis, gluconeogenesis                            \<0.002                  \<0.003
  **BioCarta:** h_ecmPathway                            Erk and PI-3 kinase in collagen binding                \<0.004                  \<0.043
  **BioCarta:** h_p53hypoxiaPathway                     Hypoxia and p53 in the cardiovascular system           \<0.03                   \<0.003
  **CaCo-2**[b](#tfn4-btt-2-329){ref-type="table-fn"}                                                                                   
  **BioCarta:** h_erkPathway                            Erk1/Erk2 Mapk signaling                               \<0.00002                \<0.014
  **BioCarta:** h_igf1rPathway                          Antiapoptotic pathways from Igf-1 receptor signaling   \<0.001                  \<0.002
  **BioCarta:** h_il2Pathway                            Il-2 signaling pathway                                 \<0.002                  \<0.053
  **BioCarta:** h_biopeptidesPathway                    Bioactive peptide induced aignaling pathway            \<0.003                  \<0.04
  **BioCarta:** h_barr-mapkPathway                      Arrestins and activation of Map kinases                \<0.003                  \<0.22
  **BioCarta:** h_her2Pathway                           Erbb2 in signal transduction and oncology              \<0.004                  \<0.06

**Notes:** **^a^**Pathway accession under: <http://www.genome.jp/kegg/pathway.html> and <http://www.biocarta.com/>. Please use Pathway Id to retrieve pathways and the associated genes

^b^ the RARA pathway was detected using PathwayAssist software and is not listed on this table.

###### 

Comparison of the expression trends between microarray and OPCR data

  Fold-induction ratio: coxP vs. coxN cells           
  ------------------------------------------- ------- -------
  **Ratio HT-29/coxN**                                
  PRNP                                        0.741   0.625
  LAMR1                                       0.828   0.675
  NFE2L2                                      0.783   0.842
  **Ratio CaCo2/coxN**                                
  RARA                                        3.221   1.776
  CTSD                                        4.053   3.099
  UBE1L                                       1.220   2.660
  THBS                                        2.320   2.632
  ITGB4                                       1.831   2.651
  MAP1A                                       2.065   1.608
  **Ratio HCA-7/coxN**                                
  AKT1                                        0.809   1.196
  MAPK8                                       1.597   0.788
  HIF1A                                       0.805   0.839
  IGFBP3                                      0.478   0.559
  FHL2                                        0.695   0.634
  **Ratio coxP/coxN**                                 
  WIF                                         1.471   1.549
  SMAD4                                       1.320   1.668
  GSK3B                                       0.756   1.133
  TLE1                                        1.298   1.802
  MYC                                         0.565   0.664

###### 

Pathways affected by APHS in the group of coxP cell lines

  Pathway Id[a](#tfn5-btt-2-329){ref-type="table-fn"}   Description                                                LS permutation p-value   KS permutation p-value
  ----------------------------------------------------- ---------------------------------------------------------- ------------------------ ------------------------
  **Kegg:** hsa00970                                    Aminoacyl-tRNA biosynthesis                                \<0.0007                 \<0.02
  **BioCarta:** h_il2Pathway                            IL 2 signaling pathway                                     \<0.003                  \<0.004
  **Kegg:** hsa00360                                    Phenylalanine metabolism                                   \<0.004                  \<0.007
  **BioCarta:** h_wntPathway                            WNT signaling pathway                                      \<0.005                  \<0.05
  **BioCarta:** h_nkcellsPathway                        Ras-independent pathway in NK cell-mediated cytotoxicity   \<0.007                  \<0.003

**Notes:** **^a^**Pathway accession under: <http://www.genome.jp/kegg/pathway.html> and <http://www.biocarta.com/>. Please use Pathway Id to retrieve pathways and the associated genes.
